US3542820A - Alpha,omega - alkanediolphosphorylalkanolamine derivatives and process for preparing thereof - Google Patents

Alpha,omega - alkanediolphosphorylalkanolamine derivatives and process for preparing thereof Download PDF

Info

Publication number
US3542820A
US3542820A US765976A US3542820DA US3542820A US 3542820 A US3542820 A US 3542820A US 765976 A US765976 A US 765976A US 3542820D A US3542820D A US 3542820DA US 3542820 A US3542820 A US 3542820A
Authority
US
United States
Prior art keywords
octadeca
trienoyl
propanediol
derivatives
alkanediolphosphorylalkanolamine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US765976A
Inventor
Sumanas Rakhit
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
American Home Products Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Products Corp filed Critical American Home Products Corp
Application granted granted Critical
Publication of US3542820A publication Critical patent/US3542820A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl

Definitions

  • This invention relates to new alkanediolphosphorylalkanolamine derivatives and to a process used for their synthesis.
  • this invention relates to alkanediolphosphorylalkanolamine derivatives of Formula I,
  • R represents a carboxylic acyl group containing 18 to 20 carbon atoms and three or four double bonds, such as, for example, an octadeca-'6,9,l2-trienoyl, octadeca 9,12,15 trienoyl, octadeca-6,9,12,15-tetraenoyl, eicosa 8,11,14 trienoyl or an eicosa-5,8,ll,14-tetraenoyl group; m represents the integers zero, one or two; n represents the integers one or two; and R represents a hydrogen atom or a lower alkyl group, such as, for example, a methyl group.
  • alkanediolphosphorylalkanolamine derivatives of this invention have been found to possess pharmacological properties which render them useful as medicinal agents. More particularly, these derivatives exhibit utility as antihypertensive agents when tested in standard pharmacological tests. For example, when these derivatives are administered to renal hypertensive rats, obtained by the method of A. Grollman, Proc. Soc. Exptl. Biol. Med., 57, 102 (1944), reduction of blood pressure 1 toward normal levels is observed. This fall in blood pressure is readily measured by the method of H. Kersten et al., J. Lab. Clin. Med., 32 1090 (1947).
  • the compounds of this invention of Formula I are employed as antihyptertensive agents in warm-blooded animals, e.g. rats, alone or in combination with pharmacologically acceptable carriers, the proportion of which is determined by the solubility and chemical nature of the compound, chosen route of administration and standard biological practice.
  • they may be administered orally in solid form containing such excipients as starch, milk sugar, certain types of clay and so forth.
  • They may also be administered orally in the form of solutions or they may be injected parenterally.
  • parenteral administration they may be used in the form of a sterile solution containing other solutes, for example, enough saline or glucose to make the solution isotonic.
  • the dosage of the present therapeutic agents will vary with the form of administration and the particular compound chosen. Furthermore, it will vary with the particular host under treatment. Generally, treatment is initiated with small dosages substantially less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstances is reached.
  • the compounds of this invention are most desirably administered at a concentration level that will generally afford effective results without causing any harmful or deleterious side effects and preferably at a level that is in a range of from about 0.3 mg. to about mg. per kilo per day, although as aforementioned variations will occur. However, a dosage level that is in the range of from about 3 mg. to about 10 mg. per kilo per day is most satisfactory. Such doses may be administered once or twice a day, as required.
  • a noteworthy aspect of this invention is the discovery that a minimum of three double bonds must be present in the acyl group of the alkanediolphosphorylalkanolamines of Formula I before said compounds exhibit antihyptertensive activity.
  • 1-octadeca-9,l2-di enoyl 1,3, propanediol 3 phosphoryl-Z-ethanolamine (containing two double bonds in the acyl group) (I;
  • octadeca 9,12 dienoyl-1,3-propanediol-3- phosphoryl-Z-ethanolamine is prepared by the same process described below, for the compounds of this invention except that octadeca-9,12-dienoyl chloride, described by C. H. Allen et al., Org. Syntheses, 37, 66(1957), is used as the acylating agent.
  • the starting material of Formula II is 1,2-ethanedil, 1,3-propanediol or 1,4-butanediol, described in Rodds Chemistry of Carbon Compounds, second edition, S. Coffey, Editor, Elsevier Publishing Company, New York, 1965, pp. 11-14.
  • an excess, preferably fiveto fifteen-fold, of the starting material of Formula II is treated with an acylating agent, such as, for example, an appropriate acid chloride, in the presence of an acid acceptor, preferably pyridine, to afford the monoacylated derivative of Formula III in which R is as defined above.
  • an acylating agent such as, for example, an appropriate acid chloride
  • the preferred acylating agents for the above reactions are the corresponding acid chlorides, prepared from the appropriate acids, according to the method used by W. Stoffel and H. D. Pruss, J. Lipid Res., 8, 196 (1967) for the preparation of octadeca-6,9,12-trienoyl chloride.
  • Such acids are octadeca-6,9,12-trienoic acid, described by I. M. Osbond and J. C. Wickers, Chem. and Ind., 1287 (1959); octadeca-9,12,15-trienoic acid, described by S. S. Nigam and B. C. L. Weedon, Chem.
  • the monoacylated derivative of Formula III is condensed with phosphorus oxychloride in the presence of an organic base, preferably quinoline, followed by treatment with an appropriate hydroxyalkylcarbamic acid tert-butyl ester, described below, to afford the phosphoric acid ester of Formula IV in which R R m and n are as defined above and Z represents a primary amino group coupled with a tert-butyloxycarbonyl group.
  • hydroxyalkylcarbarnic acid tert-butyl esters preferred in the above reaction are Z-hydroxyethylcarbamic acid tert-butyl ester, described by F. I. M. Daemen et a1., Rec. Trav. Chim., 82, 487 (1963), 3-hydroxypropylcarbamic acid tert-butyl ester, 2-hydroxypropylcarbamic acid tert-butyl ester and 3-hydroxybutylcarbamic acid tert-butyl ester.
  • the latter three esters may be readily prepared according to the procedure of F. I. M. Daemen et al., cited above, used for the preparation of the former ester.
  • the phosphoric acid esters of Formula IV are readily converted to the alkanediolphosphorylalkanolamine derivatives of Formula I by conventional methods such as those described by E. Schroder and K. Lubke, cited above, see page 39; the use of hydrogen chloride in ether solution is a preferred conventional method.
  • EXAMPLE 1 To a cold solution of 5.0 g. of 1,3-propanediol in 50 ml. of dry chloroform, 5.0 g. of octadeca-9,12,15-trienoyl chloride and 20 ml. of pyridine are added. The mixture is allowed to stand at room temperature for 18 hours. The solution is diluted with chloroform, washed with 2 N hydrochloric acid and Water, dried over anhydrous sodium sulfate, filtered and evaporated to dryness to yield 5.8 g. of an oil. The residual oil is subjected to chromatography on silica gel.
  • the monoacylated derivatives 1-octadeca-6,9,l2-trienoyl-, 1- octadeca-9,12,15-trienoyl 1-octadeca-6,9,12,15-tetraenoy1-, 1-eicosa-8,1l,l4-trienoyl-, 1-eicosa-5,8,11,14-tetraenoyl-1,2-ethanediol and -l,4-butanediol, are obtained.
  • These monoacylated derivatives are readily characterized by their infrared spectra which show absorption bands similar to those reported above for 1-octadeca-9,12,15- trienoyl-l,3-propanediol.
  • alkanediolphosphorylalkanolamines are readily characterized by their infrared spectra which show absorption bands similar to those reported above for 1-octadeca-9,12,15- trienoyl-1,3-propanediol-3-phosphoryl-2-ethanolamine.
  • alkanediolphosphorylalkanolamines are readily characterized by their infrared spectra which show absorption bands similar to those reported above for 1-octadeca-9,12,15-trienoyl-1,3- propanediol-3-phosphoryl-2-ethanolamine.
  • teger selected from the group which consists of 1 and 2; and R is selected from the group which consists of hydrogen and lower alkyl.

Description

United States Patent a,w ALKANEDIOLPHOSPHORYLALKANOLAMINE DERIVATIVES AND PROCESS FOR PREPARING THEREOF Sumanas Rakhit, Dollard des Ormeaux, Quebec, Canada, assignor to American Home Products Corporation, New York, N.Y., a corporation of Delaware No Drawing. Filed Oct. 8, 1968, Ser. No. 765,976
Int. Cl. C07f 9/08 US. Cl. 260-403 3 Claims ABSTRACT OF THE DISCLOSURE There are disclosed alkanediolphosphorylalkanolamine derivatives of the formula in which R represents a carboxylic acyl group containing 18 to 20 carbon atoms and three or four double bonds, in represents the integers zero, one or two, It represents the integers one or two, and R represents a hydrogen atom or the methyl group. Those compounds possess antihypertensive activities, and methods for their preparation and use are also disclosed.
This invention relates to new alkanediolphosphorylalkanolamine derivatives and to a process used for their synthesis.
More specificaly, this invention relates to alkanediolphosphorylalkanolamine derivatives of Formula I,
in which R represents a carboxylic acyl group containing 18 to 20 carbon atoms and three or four double bonds, such as, for example, an octadeca-'6,9,l2-trienoyl, octadeca 9,12,15 trienoyl, octadeca-6,9,12,15-tetraenoyl, eicosa 8,11,14 trienoyl or an eicosa-5,8,ll,14-tetraenoyl group; m represents the integers zero, one or two; n represents the integers one or two; and R represents a hydrogen atom or a lower alkyl group, such as, for example, a methyl group.
The alkanediolphosphorylalkanolamine derivatives of this invention have been found to possess pharmacological properties which render them useful as medicinal agents. More particularly, these derivatives exhibit utility as antihypertensive agents when tested in standard pharmacological tests. For example, when these derivatives are administered to renal hypertensive rats, obtained by the method of A. Grollman, Proc. Soc. Exptl. Biol. Med., 57, 102 (1944), reduction of blood pressure 1 toward normal levels is observed. This fall in blood pressure is readily measured by the method of H. Kersten et al., J. Lab. Clin. Med., 32 1090 (1947).
When the compounds of this invention of Formula I are employed as antihyptertensive agents in warm-blooded animals, e.g. rats, alone or in combination with pharmacologically acceptable carriers, the proportion of which is determined by the solubility and chemical nature of the compound, chosen route of administration and standard biological practice. For example, they may be administered orally in solid form containing such excipients as starch, milk sugar, certain types of clay and so forth.
They may also be administered orally in the form of solutions or they may be injected parenterally. For parenteral administration they may be used in the form of a sterile solution containing other solutes, for example, enough saline or glucose to make the solution isotonic.
The dosage of the present therapeutic agents will vary with the form of administration and the particular compound chosen. Furthermore, it will vary with the particular host under treatment. Generally, treatment is initiated with small dosages substantially less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstances is reached. In general, the compounds of this invention are most desirably administered at a concentration level that will generally afford effective results without causing any harmful or deleterious side effects and preferably at a level that is in a range of from about 0.3 mg. to about mg. per kilo per day, although as aforementioned variations will occur. However, a dosage level that is in the range of from about 3 mg. to about 10 mg. per kilo per day is most satisfactory. Such doses may be administered once or twice a day, as required.
A noteworthy aspect of this invention is the discovery that a minimum of three double bonds must be present in the acyl group of the alkanediolphosphorylalkanolamines of Formula I before said compounds exhibit antihyptertensive activity. For example, 1-octadeca-9,l2-di enoyl 1,3, propanediol 3 phosphoryl-Z-ethanolamine (containing two double bonds in the acyl group) (I;
m:1, n=1 and R =H) when administered by injection at a daily dose of 1 to 10 mg./kg. for five days does not show an antihypertensive effect in renal hyptertensive rats according to the method of Kersten et al., cited above; whereas, 1 -octadeca 9,12,15 trienoyl-1,3 propanediol-3-ph0sphoryl-2-ethanolamine (containing three double bonds in the acyl group) [1;
m=1, n=1 and R =H], a compound of this invention, exhibits a profound antihypertensive effect at these dose levels. 1 octadeca 9,12 dienoyl-1,3-propanediol-3- phosphoryl-Z-ethanolamine is prepared by the same process described below, for the compounds of this invention except that octadeca-9,12-dienoyl chloride, described by C. H. Allen et al., Org. Syntheses, 37, 66(1957), is used as the acylating agent.
More specifically, I prefer to prepare the alkanediolphosphorylalkanolamine derivatives of this invention by the process illustrated by the following formulae:
011 011 CHzO R Qm H2);
CHZOH CH OH II III (31120115 CHzOR H2)m 2)m ll I II H2O-PO-CH(CH2) Z CH20"POCH(CH2)11NH2 OH R OH R IV I in which R R m and n are as defined above and Z represents a primary amino group coupled with an amineprotecting group, such as, preferably a tert-butyloxycarbonyl group or some other amine-protecting group, for example, such as those described by 'E. Schrdder and K. Liibke in The Peptides, vol. I, Academic Press, New York, 1965, pp. 3-51.
The starting material of Formula II is 1,2-ethanedil, 1,3-propanediol or 1,4-butanediol, described in Rodds Chemistry of Carbon Compounds, second edition, S. Coffey, Editor, Elsevier Publishing Company, New York, 1965, pp. 11-14.
In employing the process illustrated above for the preparation of the compounds of this invention of Formula I, an excess, preferably fiveto fifteen-fold, of the starting material of Formula II, is treated with an acylating agent, such as, for example, an appropriate acid chloride, in the presence of an acid acceptor, preferably pyridine, to afford the monoacylated derivative of Formula III in which R is as defined above.
The preferred acylating agents for the above reactions are the corresponding acid chlorides, prepared from the appropriate acids, according to the method used by W. Stoffel and H. D. Pruss, J. Lipid Res., 8, 196 (1967) for the preparation of octadeca-6,9,12-trienoyl chloride. Such acids are octadeca-6,9,12-trienoic acid, described by I. M. Osbond and J. C. Wickers, Chem. and Ind., 1287 (1959); octadeca-9,12,15-trienoic acid, described by S. S. Nigam and B. C. L. Weedon, Chem. and 1nd, 155 (1955); octadeca-6,9,12,15-tetraenoic acid, described by M. Matic, Biochem. J., 68, 692 (1958); eicosa-8,l1,14- trienoic acid, described by W. Stoffel, Ann. Chem., 673, 26 (1964); and eicosa-5,8,11,14-tetraenoic acid, described by J. M. Osbond and J. C. Wickers, cited above.
The monoacylated derivative of Formula III is condensed with phosphorus oxychloride in the presence of an organic base, preferably quinoline, followed by treatment with an appropriate hydroxyalkylcarbamic acid tert-butyl ester, described below, to afford the phosphoric acid ester of Formula IV in which R R m and n are as defined above and Z represents a primary amino group coupled with a tert-butyloxycarbonyl group.
The appropriate hydroxyalkylcarbarnic acid tert-butyl esters preferred in the above reaction are Z-hydroxyethylcarbamic acid tert-butyl ester, described by F. I. M. Daemen et a1., Rec. Trav. Chim., 82, 487 (1963), 3-hydroxypropylcarbamic acid tert-butyl ester, 2-hydroxypropylcarbamic acid tert-butyl ester and 3-hydroxybutylcarbamic acid tert-butyl ester. The latter three esters may be readily prepared according to the procedure of F. I. M. Daemen et al., cited above, used for the preparation of the former ester. When employing this procedure for this purpose, an equivalent amount of 3-amino-lpropanol, described by L. Henry, Chem. Ber., 33, 3169 (1900), 1-amino-2-propanol, described by P. -A. Levene and J. Scheidegger, J. Biol. Chem., 60, 172 (1924) and 4-amino-2-butanol, described by R. Robinson and H. Suginome, in J. Chem. Soc., 304 (1932), is used instead of ethanolamine to obtain the corresponding hydroxyalkylcarbamic acid tert-butyl ester, respectively.
Finally, the phosphoric acid esters of Formula IV are readily converted to the alkanediolphosphorylalkanolamine derivatives of Formula I by conventional methods such as those described by E. Schroder and K. Lubke, cited above, see page 39; the use of hydrogen chloride in ether solution is a preferred conventional method.
The following examples will illustrate this invention.
EXAMPLE 1 To a cold solution of 5.0 g. of 1,3-propanediol in 50 ml. of dry chloroform, 5.0 g. of octadeca-9,12,15-trienoyl chloride and 20 ml. of pyridine are added. The mixture is allowed to stand at room temperature for 18 hours. The solution is diluted with chloroform, washed with 2 N hydrochloric acid and Water, dried over anhydrous sodium sulfate, filtered and evaporated to dryness to yield 5.8 g. of an oil. The residual oil is subjected to chromatography on silica gel. Elution with benzene affords a small amount of the diacylated derivative, 1,3-dioctadeca- 9,12,1S-trienoyl-1,3-propanediol. Subsequent elution with 2% ethyl acetate in benzene affords the desired monoacylated derivative, 1 octadeca-9,12,15-trienoyl-1,3-propanediol (III, R =CH (CH CH=CH) 3 (CH 7C0) 3400, 1745 and 1670 cm.-
In the same manner, but using an equivalent amount of the acid chlorides, octadeca-6,9,12-trienoyl chloride, octadeca-6,9,12,15-tetraenoyl chloride, eicosa-8,l1,14- trienoyl chloride or eicosa-5,8,11,14-tetraenoyl chloride instead of octadeca-9,12,15-trienoyl chloride, the corresponding monoacylated derivatives, 1-octadeca6,9,12- trienoyl-, 1-octadeca-6,9,l2,l5-tetraenoyl, 1-eicosa-8,1l, l4-trienoyland -eicosa-5,8,11,l4-tetraenoyl-1,3-propanediol, are obtained. These monoacylated derivatives are readily characterized by their infrared spectra which show absorption bands similar to those reported above for 1- octadeca-9,12,l5-trienoyl-1,3-propanediol.
In the same manner, but using an equivalent amount of 1,2-ethanedio1 or 1,4-butanediol, instead of 1,3-propanediol, together with the appropriate acid chloride, the monoacylated derivatives, 1-octadeca-6,9,l2-trienoyl-, 1- octadeca-9,12,15-trienoyl 1-octadeca-6,9,12,15-tetraenoy1-, 1-eicosa-8,1l,l4-trienoyl-, 1-eicosa-5,8,11,14-tetraenoyl-1,2-ethanediol and -l,4-butanediol, are obtained. These monoacylated derivatives are readily characterized by their infrared spectra which show absorption bands similar to those reported above for 1-octadeca-9,12,15- trienoyl-l,3-propanediol.
EXAMPLE 2 To 1.288 g. of freshly distilled phosphorus oxychloride, in 50 ml. of dry chloroform, cooled to 10, a solution of 2.79 g. of 1-octadeca-9,12,15-trienoyl-1,3-propanediol, prepared as described in Example 1 and 1.18 g. of quinoline in 50 ml. of dry chloroform are added over a period of 30 minutes. The reaction mixture is kept at 25 for two hours after which it is again cooled to 0 and a solution of 1.18 g. of 2-hydroxyethylcarbarnic acid tert butyl ester and 1.2 g. of pyridine in 50 ml. of dry chloroform are added over a period of 30 minutes. The reaction mixture is allowed to stand at room temperature for 24 hours. Water (0.6 ml.) is added and the reaction mixture is stirred for one hour, washed with cold 2 N hydrochloric acid and water, dried over anhydrous sodium sulfate, filtered and evaporated to dryness. The residual oil, the phosphoric acid ester, l-octadeca- 9,12,15 trienoyl-1,3-propanediol-3-phosphoryl-N-(tertbutyloxycarbonyl)-ethanolamine [IV;
max.
3400-3500, 1745, 1700 and 1695 cm.- shows essentially one spot on thin layer chromatography This phosphoric acid ester is dissolved in 50 ml. of dry chloroform and treated with a stream of dry hydrogen chloride for two hours. The solvent is then removed under reduced pressure. The oily residue is dissolved in a mixture of ethanol:ether:water:24:2:1 and passed through a column of IR45 ,(OH" cycle) ion exchange resin. Evaporation of the filtrate yields an oil which is subjected to chromatography on 60 g. of silica gel. Elution with 2-5 percent methanol in chloroform yield the desired alkanediolphosphorylalkanolamine, 1 octadeca 9,12,15-trienoyl 1,3-propanediol-3-phosphoryl-2-ethanolamine (I; R =CH (CH CH=CH) (CH CO, m=1, n'=1 and R 3400-3500, 1745 and 1650 cmr In the same manner, but using an equivalent amount of the hydroxyalkylcarbamic acid tert-butyl esters, 3-hydroxypropyl-, Z-hydroxypropyland 3-hydroxybutyl-carbamic acid tert'buty1 ester, described above, instead of 2- hydroxyethylcarbamic acid tert-butyl ester, the corresponding alkanediolphosphorylalkanolamines, l-octadeca- 9,12,15-trienoyl 1,3-propanediol 3-phosphoryl 3-hydroxypropylamines, -2-hydroxypropylamine and -3-hydroxybutylamine, are obtained, respectively. These alkanediolphosphorylalkanolamines are readily characterized by their infrared spectra which show absorption bands similar to those reported above for 1-octadeca-9,12,15- trienoyl-1,3-propanediol-3-phosphoryl-2-ethanolamine.
In the same manner, but using an equivalent amount of the appropriate monoacylated derivative prepared as described in Example 1, 1-octadeca-6,9,12-trienoyl-, 1-Octadeca 6,9,12,15-tetraenoyl-, 1-eicosa-8,11,14-trienoylor 1 eicosa-5,8,11,14-tetraenoyl-1,3-propanedio1 instead of octadeca-9,12,15-trienoyl-1,3-propanedio1, together with the appropriate hydroxyalkylcarbamic acid tert-butyl ester, the corresponding alkanediolphosphorylalkanolarnines, 1-octadeca-6,9,12-trienoyl-, octadeca-6,9,12,15-tetraenoyl-, eicosa-8,11,14-trienoyl-, eicosa-5,8,11,14-tetraenoyl-l,3-propanediol-3-phosphoryl-Z-ethanolamines, -3-hydroxypropylamines, -2-hydroxypropylamines and -3-hydroxybutylamines, are obtained. These alkanediolphosphorylalkanolamines are readily characterized by their infrared spectra which show absorption bands similar to those reported above for 1-octadeca-9,12,15-trienoyl-1,3- propanediol-3-phosphoryl-2-ethanolamine.
In the same manner, but using an equivalent amount of 1,2-ethanediol or 1,4-butanediol-instead of 1,3-propanediol, together with the appropriate monoacyl derivative prepared as described in Example 1, and the appropriate hydroxyalkylcarbamic acid tert-butyl ester, described above, the alkanediolphosphorylalkanolamines, l-octadeca-6,9,12-trienoyl-, 1-octadeca-9,12,15-trien0yl-, l-octadeca-6,9,12,15-tetraenoyl-, l-eicosa- 8,11,14-trienoyl-, 1- eicosa-5,8,11,14-tetraenoyl 1,2-ethanediol-2-phosphoryl and -1,4-butanediol 4-phosphory1 Z-ethanolamines, 3- hydroxypropylamines, -2-hydroxypropylamines and -3-hydroxybutylamines, are obtained. These alkanediolphosphoryalkanolamines are readily characterized by their infrared spectra which show absorption bands similar to those reported above for 1-octadeca 9,12,15-trienoyl-,l,
3-propanediol-3 -phosphoryl-2-ethanolamine.
I claim:
1. A compound selected from those of the formula onion (cm)...
teger selected from the group which consists of 1 and 2; and R is selected from the group which consists of hydrogen and lower alkyl.
2. l-octadeca 9,12,15-trienoy1 1,3-propanediol 3- phosphoryl-Z-ethanolamine.
3. The process which comprises treating a compound selected from the group which consists of 1,2-ethanediol, 1,3-propanediol and 1,4-butanediol with an acylating agent in the presence of an acid acceptor, thereby securing a monoacylated compound of the formula wherein R represents a carboxylic acyl group containing from eighteen to twenty carbon atoms and having three or four double bonds, and m is an integer selected from 0, 1 and 2; condensing said monoacylated compound first with phosphorus oxychloride in the presence of an organic base, and then treating the reaction mixture with a hydroalkylcarbamic acid tert-butyl ester, thereby securing a compound of the formula wherein R and m are as above defined, n is an integer selected from the group which consists of 1 and 2, R is selected from the group consisting of hydrogen and lower alkyl, and Z represents a primary amino group coupled with a tert-butyloxycarbonyl group; and treating said lastnamed compound with hydrogen chloride under substantially anhydrous conditions, thereby securing a compound of the formula ll GH2OPOCH(CH2)nNHz OH R wherein R m, n and R are as above defined.
References Cited UNITED STATES PATENTS 3,031,478 4/1962 Klenk et a1. 260403 3,162,668 12/1964 Reed et a1 260-403 X CHARLES E. PARKER, Primary Examiner R. L. RAYMOND, Assistant Examiner US. Cl. X.R.
@3 3 UNITED STATES PATENT OFFICE CERTIFICATE OF CORRECTION Patent No. 3,54 ,8 Dated November 4, 197
Inventor s) Sumanas R khi'b It is certified that error appears in the above-identified patent and that said Letters Patent are hereby corrected as shown below:
In Column 5, lines 50-53, in the right hand portion of the claimed formula, the subscript "m" should be n whereby said portion of the formula should read:
-- --CH(CH NH Signed and sealed this 13th day of April 1 971 (SEAL) Attest:
EDwARD M.FLETCIER,JR. WILLIAM E. SCHUYLER, Attesting Officer Commissioner of Pate
US765976A 1968-10-08 1968-10-08 Alpha,omega - alkanediolphosphorylalkanolamine derivatives and process for preparing thereof Expired - Lifetime US3542820A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US76597668A 1968-10-08 1968-10-08

Publications (1)

Publication Number Publication Date
US3542820A true US3542820A (en) 1970-11-24

Family

ID=25075033

Family Applications (1)

Application Number Title Priority Date Filing Date
US765976A Expired - Lifetime US3542820A (en) 1968-10-08 1968-10-08 Alpha,omega - alkanediolphosphorylalkanolamine derivatives and process for preparing thereof

Country Status (1)

Country Link
US (1) US3542820A (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3694473A (en) * 1970-07-06 1972-09-26 Hansjorg E Eibl Higher alkano yl-propanediol-(1,3)-2 -trimethylammonium-ethyl phosphates
US3694474A (en) * 1970-07-06 1972-09-26 Boehringer Sohn Ingelheim Higher alkano yl-propanediol-(1,3)-phosphoric acid-choline esters
US3875196A (en) * 1970-12-28 1975-04-01 Ajinomoto Kk Process for preparing phosphoric acid esters of fatty acid mono- or di-glycerides
EP0043472A1 (en) * 1980-07-08 1982-01-13 A. Nattermann & Cie. GmbH 3-Hydrocarbylthio-2-acyloxypropyl 2-trimethylammonioethyl phosphates, process for producing the same and pharmaceutical preparations containing the same
EP0121088A1 (en) * 1983-03-05 1984-10-10 A. Nattermann & Cie. GmbH New o-acyl-alkanediol-phospholipids, processes for their preparation and pharmaceutical preparations containing them
US4493832A (en) * 1981-07-03 1985-01-15 Fujisawa Pharmaceutical Co., Ltd. Certain glycerol-phosphoryl choline derivatives, compositions containing same and method of using same
US4534899A (en) * 1981-07-20 1985-08-13 Lipid Specialties, Inc. Synthetic phospholipid compounds

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3031478A (en) * 1957-07-09 1962-04-24 Nattermann A & Cie Process for the production of natural phospholipids and substances produced thereby
US3162668A (en) * 1962-10-18 1964-12-22 Texaco Inc Hydrocarbonthio-phosphonoxydihydroxyalkoxyalkyl alkenoates

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3031478A (en) * 1957-07-09 1962-04-24 Nattermann A & Cie Process for the production of natural phospholipids and substances produced thereby
US3162668A (en) * 1962-10-18 1964-12-22 Texaco Inc Hydrocarbonthio-phosphonoxydihydroxyalkoxyalkyl alkenoates

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3694473A (en) * 1970-07-06 1972-09-26 Hansjorg E Eibl Higher alkano yl-propanediol-(1,3)-2 -trimethylammonium-ethyl phosphates
US3694474A (en) * 1970-07-06 1972-09-26 Boehringer Sohn Ingelheim Higher alkano yl-propanediol-(1,3)-phosphoric acid-choline esters
US3875196A (en) * 1970-12-28 1975-04-01 Ajinomoto Kk Process for preparing phosphoric acid esters of fatty acid mono- or di-glycerides
EP0043472A1 (en) * 1980-07-08 1982-01-13 A. Nattermann & Cie. GmbH 3-Hydrocarbylthio-2-acyloxypropyl 2-trimethylammonioethyl phosphates, process for producing the same and pharmaceutical preparations containing the same
US4493832A (en) * 1981-07-03 1985-01-15 Fujisawa Pharmaceutical Co., Ltd. Certain glycerol-phosphoryl choline derivatives, compositions containing same and method of using same
US4534899A (en) * 1981-07-20 1985-08-13 Lipid Specialties, Inc. Synthetic phospholipid compounds
EP0121088A1 (en) * 1983-03-05 1984-10-10 A. Nattermann & Cie. GmbH New o-acyl-alkanediol-phospholipids, processes for their preparation and pharmaceutical preparations containing them

Similar Documents

Publication Publication Date Title
US3577446A (en) Phosphatidylalkanolamine derivatives
Ortiz de Montellano et al. N-Methylprotoporphyrin IX: chemical synthesis and identification as the green pigment produced by 3, 5-diethoxycarbonyl-1, 4-dihydrocollidine treatment.
US4119714A (en) Glycerin-alkylether-(1)-phosphoric acid-(3)-monocholine esters as enhancers of the natural resistance of the mammalian organism against non-carcinogenic pathogens
US3708558A (en) Monochlorine ester of 3-octadecyloxy-propanol-(1)-phosphoric acid
CZ99698A3 (en) Heterocyclic derivatives with indoline, indole or tetrahydroquinoline cycle and their pharmaceutical use
US3542820A (en) Alpha,omega - alkanediolphosphorylalkanolamine derivatives and process for preparing thereof
FI84061B (en) FOERFARANDE FOER FRAMSTAELLNING AV TERAPEUTISKT AKTIVA GENTAMYCINSALTER AV FOSFORSYRAESTRAR AV 6-HYDROXIFLAVANONER.
US3694473A (en) Higher alkano yl-propanediol-(1,3)-2 -trimethylammonium-ethyl phosphates
Christensen et al. Synthesis and transport applications of 3-aminobicyclo [3, 2, 1] octane-3-carboxylic acids
Oatis Jr et al. Synthesis of quinazoline analogs of folic acid modified at position 10
SU812181A3 (en) Method of preparing cyclic derivatives of 1,4-benzoxazine or their acid-additive salts
US4725588A (en) Alkyl phospholipid antihypertensive agents in method of lowering blood pressure
US4442124A (en) Valproic acid ester with antiepileptic and anticonvulsant activity and pharmaceutical compositions therefrom
IE59283B1 (en) Pharmaceutical composition for the therapy of cerebropathies on functional and organic base
GB2037772A (en) P-acetamido phenyl phosphate and its salts
SU1225487A3 (en) Method of producing 1,2,5-dianhydro-3,4-bis-(beta-carboxy-propionyl)-dulcitol or disodium salt thereof
FI66366C (en) OIL FRAMSTAELLNING AV SOM LAEKEMEDEL ANVAENDA 1,4-THIAZINE-3-CARBOXYL SYRADERIVAT
Musson et al. Synthetic and preliminary hemodynamic and whole animal toxicity studies on (R, S)-,(R)-, and (S)-2-methyl-3-(2, 4, 5-trihydroxyphenyl) alanine
Piantadosi et al. Synthesis of acyl dihydroxyacetone phosphates and related derivatives
JPH04502149A (en) 2-Aminocarboxylic acids and their derivatives, their preparation methods and their use as medicines
SU1447283A3 (en) Method of producing condensed derivatives of as-triazine
US3971798A (en) Pyridine derivative, processes of preparation and pharmaceutical compositions
US4803219A (en) 1,3-propanediamine derivatives and antiauhythnic pharmaceutical composition containing them
CA1087193A (en) 2- (dimethylamino)(3-pyridyl)methyl -cyclohexanol and related compounds
CN107445872B (en) Compound with potential brain targeting property and preparation method and application thereof